
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4173967/publications.pdf Version: 2024-02-01



Διι Δ Ριζνι

#	Article	lF	CITATIONS
1	The evolution of an integrated ultrasound curriculum (iUSC) for medical students: 9-year experience. The Ultrasound Journal, 2015, 7, 18.	2.0	129
2	GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 2814-2821.	1.8	104
3	Cytokine Biomarkers, Endothelial Inflammation, and Atherosclerosis in the Metabolic Syndrome: Emerging Concepts. American Journal of the Medical Sciences, 2009, 338, 310-318.	0.4	99
4	Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. Cardiovascular Diabetology, 2016, 15, 162.	2.7	98
5	An Overview of Insulin Pumps and Glucose Sensors for the Generalist. Journal of Clinical Medicine, 2016, 5, 5.	1.0	92
6	Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovascular Diabetology, 2014, 13, 49.	2.7	86
7	Liraglutide Reduces Oxidative Stress And Restores Heme Oxygenase-1 and Ghrelin Levels in Patients with Type 2 Diabetes: A Prospective Pilot Study. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 603-606.	1.8	84
8	Perioperative Management of Diabetes and Hyperglycemia in Patients Undergoing Orthopaedic Surgery. Journal of the American Academy of Orthopaedic Surgeons, The, 2010, 18, 426-435.	1.1	83
9	Diabetes and the COVID-19 Pandemic: How Insights from Recent Experience Might Guide Future Management. Metabolic Syndrome and Related Disorders, 2020, 18, 173-175.	0.5	79
10	Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. Expert Opinion on Investigational Drugs, 2009, 18, 1495-1503.	1.9	73
11	Severe Primary Hypothyroidism Manifesting with Torsades De Pointes. American Journal of the Medical Sciences, 2006, 331, 154-156.	0.4	64
12	Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect. Diabetes Therapy, 2021, 12, 261-274.	1.2	41
13	Combined Dyslipidemia: Should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia?. Current Pharmaceutical Design, 2013, 19, 3858-3868.	0.9	41
14	Promoting a Syndemic Approach for Cardiometabolic Disease Management During COVID-19: The CAPISCO International Expert Panel. Frontiers in Cardiovascular Medicine, 2021, 8, 787761.	1.1	38
15	Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study. Expert Opinion on Biological Therapy, 2015, 15, 1391-1397.	1.4	36
16	Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors. Metabolism: Clinical and Experimental, 2020, 111, 154343.	1.5	36
17	Daily Use of Extra Virgin Olive Oil with High Oleocanthal Concentration Reduced Body Weight, Waist Circumference, Alanine Transaminase, Inflammatory Cytokines and Hepatic Steatosis in Subjects with the Metabolic Syndrome: A 2-Month Intervention Study. Metabolites, 2020, 10, 392.	1.3	34
18	Management of Diabetes in Older Adults. American Journal of the Medical Sciences, 2007, 333, 35-47.	0.4	32

#	Article	IF	CITATIONS
19	Nutritional challenges in the elderly with diabetes. International Journal of Diabetes Mellitus, 2009, 1, 26-31.	0.6	30
20	Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An 8-month prospective study. Diabetes Research and Clinical Practice, 2019, 149, 163-169.	1.1	30
21	The Relationship between COVID-19 and Hypothalamic–Pituitary–Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excess—The CAPISCO International Expert Panel. International Journal of Molecular Sciences, 2022, 23, 7326.	1.8	30
22	Future perspectives of the pharmacological management of diabetic dyslipidemia. Expert Review of Clinical Pharmacology, 2019, 12, 129-143.	1.3	29
23	Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia. Expert Opinion on Drug Safety, 2022, 21, 9-20.	1.0	29
24	Hypertension, Obesity, and Inflammation: The Complex Designs of a Deadly Trio. Metabolic Syndrome and Related Disorders, 2010, 8, 287-294.	0.5	28
25	The therapeutic modulation of atherogenic dyslipidemia and inflammatory markers in the metabolic syndrome: what is the clinical relevance?. Acta Diabetologica, 2009, 46, 1-11.	1.2	27
26	Impact of Clinical and Therapeutic Factors on Incident Cardiovascular and Cerebrovascular Events in a Populationâ€Based Cohort of <scp>HIV</scp> â€Infected and Non– <scp>HIV</scp> â€Infected Adults. Clinical Cardiology, 2014, 37, 517-522.	0.7	27
27	Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes. Journal of Clinical Medicine, 2020, 9, 912.	1.0	27
28	Incretin-Based Therapies, Glucometabolic Health and Endovascular Inflammation. Current Pharmaceutical Design, 2014, 20, 4953-4960.	0.9	27
29	Type 2 Diabetes: Epidemiologic Trends, Evolving Pathogenic Concepts, and Recent Changes in Therapeutic Approach. Southern Medical Journal, 2004, 97, 1079-1087.	0.3	26
30	Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options. Biomedicines, 2021, 9, 1579.	1.4	26
31	Levofloxacin-Induced Hypoglycemia in a Nondiabetic Patient. American Journal of the Medical Sciences, 2006, 331, 334-335.	0.4	25
32	Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 494-496.	1.0	25
33	The effects of liraglutide on glucose, inflammatorymarkersandlipoprotein metabolism: current knowledge and future perspective. Clinical Lipidology, 2013, 8, 173-181.	0.4	24
34	Novel Therapeutical Approaches to Managing Atherosclerotic Risk. International Journal of Molecular Sciences, 2021, 22, 4633.	1.8	23
35	A Review of the Cardiovascular and Anti-Atherogenic Effects of Chrelin. Current Pharmaceutical Design, 2013, 19, 4953-4963.	0.9	22
36	46, XX Man with SRY Gene Translocation: Cytogenetic Characteristics, Clinical Features and Management. American Journal of the Medical Sciences, 2008, 335, 307-309.	0.4	21

#	Article	IF	CITATIONS
37	The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2022, Volume 15, 1023-1030.	1.1	20
38	Sustained Remission with the Kinase Inhibitor Sorafenib in Stage IV Metastatic Adrenocortical Carcinoma. Endocrine Practice, 2010, 16, 441-445.	1.1	19
39	Vitamin D Deficiency in Patients with Congestive Heart Failure. Southern Medical Journal, 2011, 104, 325-330.	0.3	19
40	Headache, Pituitary Lesion and Panhypopituitarism in a Pregnant Woman: Tumor, Apoplexy or Hypophysitis?. American Journal of the Medical Sciences, 2011, 342, 247-249.	0.4	19
41	Prevalence and Impact of Initial Misclassification of Pediatric Type 1 Diabetes Mellitus. Southern Medical Journal, 2012, 105, 513-517.	0.3	18
42	The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes. Metabolism: Clinical and Experimental, 2020, 109, 154295.	1.5	18
43	The Evolving Role of Fetuin-A in Nonalcoholic Fatty Liver Disease: An Overview from Liver to the Heart. International Journal of Molecular Sciences, 2021, 22, 6627.	1.8	18
44	Pasta Supplemented with Opuntia ficus-indica Extract Improves Metabolic Parameters and Reduces Atherogenic Small Dense Low-Density Lipoproteins in Patients with Risk Factors for the Metabolic Syndrome: A Four-Week Intervention Study. Metabolites, 2020, 10, 428.	1.3	17
45	Correlations between Diabetes Mellitus Self-Care Activities and Glycaemic Control in the Adult Population: A Cross-Sectional Study. Healthcare (Switzerland), 2022, 10, 174.	1.0	17
46	Hypercalcemia Associated with Calcium Supplement Use: Prevalence and Characteristics in Hospitalized Patients. Journal of Clinical Medicine, 2015, 4, 414-424.	1.0	16
47	Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome. Current Vascular Pharmacology, 2014, 12, 572-585.	0.8	16
48	The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism. Expert Opinion on Drug Safety, 2021, 20, 1309-1315.	1.0	15
49	Novel molecular markers of cardiovascular disease risk in type 2 diabetes mellitus. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166148.	1.8	14
50	Use of Novel Antidiabetic Agents in Patients with TypeÂ2 Diabetes and COVID-19: A Critical Review. Diabetes Therapy, 2021, 12, 3037-3054.	1.2	14
51	Normocalcemic Primary Hyperparathyroidism—Characteristics and Clinical Significance of an Emerging Entity. American Journal of the Medical Sciences, 2012, 343, 163-166.	0.4	13
52	Incretins, Pregnancy, and Gestational Diabetes. Current Pharmaceutical Biotechnology, 2016, 17, 597-602.	0.9	13
53	Adipokines and Lipoproteins: Modulation by Antihyperglycemic and Hypolipidemic Agents. Metabolic Syndrome and Related Disorders, 2014, 12, 1-10.	0.5	12
54	Metabolic Syndrome: From Molecular Mechanisms to Novel Therapies. International Journal of Molecular Sciences, 2021, 22, 10038.	1.8	12

#	Article	IF	CITATIONS
55	Hypocalcemia and Parathyroid Function in Metastatic Prostate Cancer. Endocrine Practice, 2005, 11, 254-258.	1.1	11
56	"Thyrotoxic Psychosis―Associated With Subacute Thyroiditis. Southern Medical Journal, 2007, 100, 837-840.	0.3	11
57	Association of Clinical and Therapeutic Factors with Incident Dyslipidemia in a Cohort of Human Immunodeficiency Virus–Infected and Non-Infected Adults: 1994–2011. Metabolic Syndrome and Related Disorders, 2013, 11, 417-426.	0.5	11
58	Gestational Diabetes and the Metabolic Syndrome: Can Obesity and Small, Dense Low Density Lipoproteins be Key Mediators of this Association?. Current Pharmaceutical Biotechnology, 2014, 15, 38-46.	0.9	11
59	Non-glycemic effects of pioglitazone and incretin-based therapies. Expert Opinion on Therapeutic Targets, 2013, 17, 739-742.	1.5	10
60	The Risk of Developing Type 2 Diabetes Mellitus Associated With Psychotropic Drug Use in Children and Adolescents. primary care companion for CNS disorders, The, 2012, 14, .	0.2	10
61	ADDRESSING HYPERTENSION IN THE PATIENT WITH TYPE 2 DIABETES MELLITUS: PATHOGENESIS, GOALS, AND THERAPEUTIC APPROACH. European Medical Journal Diabetes, 2017, 5, 84-92.	4.0	10
62	The Use of Premixed Insulin Analogues in the Treatment of Patients with Type 2 Diabetes Mellitus: Advantages and Limitations. Insulin, 2007, 2, 68-79.	0.2	9
63	Inflammation markers as mediators of vasculo-endothelial dysfunction and atherosclerosis in the metabolic syndrome and type 2 diabetes. Chinese Medical Journal, 2007, 120, 1918-1924.	0.9	9
64	Liraglutide Increases Serum Levels of MicroRNA-27b, -130a and -210 in Patients with Type 2 Diabetes Mellitus: A Novel Epigenetic Effect. Metabolites, 2020, 10, 391.	1.3	9
65	Genetic and Epigenetic Biomarkers for Diagnosis, Prognosis and Treatment of Metabolic Syndrome. Current Pharmaceutical Design, 2021, 27, 3729-3740.	0.9	9
66	Lymphedema following breast cancer: The importance of surgical methods and obesity. Frontiers in Women's Health, 2018, 3, 195-199.	0.1	9
67	Assessment and monitoring of glycemic control in primary diabetes care: Monitoring techniques, record keeping, meter downloads, tests of average glycemia, and point-of-care evaluation. Journal of the American Academy of Nurse Practitioners, 2006, 18, 11-21.	1.4	7
68	Reconnoitering the Role of Long-Noncoding RNAs in Hypertrophic Cardiomyopathy: A Descriptive Review. International Journal of Molecular Sciences, 2021, 22, 9378.	1.8	7
69	TREATMENT OF TYPE 2 DIABETES WITH BIPHASIC INSULIN ANALOGUES. European Medical Journal Diabetes, 2016, 4, 74-83.	4.0	7
70	Cardiometabolic Alterations in the Interplay of COVID-19 and Diabetes: Current Knowledge and Future Avenues. International Journal of Molecular Sciences, 2021, 22, 12311.	1.8	7
71	Some Clues and Pitfalls in the Diagnosis of Acromegaly. Endocrine Practice, 2004, 10, 348-352.	1.1	6
72	Dapagliflozin therapy in type-2 diabetes: current knowledge and future perspectives. Expert Opinion on Pharmacotherapy, 2015, 16, 281-284.	0.9	6

#	Article	IF	CITATIONS
73	Safety and benefit of incretin-based therapies in patients with type 2 diabetes: learnings and reflections. Expert Opinion on Drug Safety, 2022, 21, 291-293.	1.0	6
74	Cardiovascular effects of glucagonâ€like peptideâ€1 receptor agonist therapies in patients with type 1 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 613-614.	2.2	5
75	Diabetes and COVID-19: A Tale of 2 Pandemics. Journal of Cardiovascular Pharmacology, 2021, 78, e1-e2.	0.8	5
76	Diabetes and COVID-19: What 2 Years of the Pandemic Has Taught Us. Metabolic Syndrome and Related Disorders, 2021, , .	0.5	5
77	Oxidative stress and small, dense low-density lipoproteins: current and future perspectives. Expert Review of Endocrinology and Metabolism, 2012, 7, 415-417.	1.2	4
78	Endocrinology in the Time of COVID-19: A Rapid Evolution of Knowledge and Care. Medicina (Lithuania), 2021, 57, 805.	0.8	4
79	Diabetic Ketoalkalosis in Children and Adults. Southern Medical Journal, 2014, 107, 6-10.	0.3	4
80	The Role of Elevated Growth Hormone on the Increased Atherosclerosis in Patients With Acromegaly. Angiology, 2012, 63, 492-494.	0.8	3
81	Microvascular and macrovascular effects of liraglutide. International Journal of Cardiology, 2019, 286, 17-18.	0.8	3
82	Impact of Comprehensive Diabetes Specialty Care in the Management of Older Adults with Stage 3 or 4 Nephropathy. Southern Medical Journal, 2009, 102, 985.	0.3	3
83	Vitamin D Levels in Patients Seen in the Diabetes Unit of an Academic Medical Center. Southern Medical Journal, 2008, 101, 1069.	0.3	3
84	Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes. Medicina (Lithuania), 2022, 58, 109.	0.8	3
85	Safety and Outcomes of Intravitreal Aflibercept in Diabetic Macular Edema – A Systematic Review. Current Pharmaceutical Design, 2022, 28, 1758-1768.	0.9	3
86	Giant Intracranial Aneurysm Masquerading in the Sella. American Journal of the Medical Sciences, 2016, 351, 119.	0.4	2
87	Inflammation markers as mediators of vasculo-endothelial dysfunction and atherosclerosis in the metabolic syndrome. Chinese Medical Journal, 2007, 120, 1918-24.	0.9	2
88	Current trends in diabetes management. JAAPA: Official Journal of the American Academy of Physician Assistants, 2005, 18, 23-29.	0.1	1
89	Eliminating Inpatient Sliding-Scale Insulin: A Reeducation Project With Medical House Staff: Response to Baldwin et al Diabetes Care, 2005, 28, 2336-2336.	4.3	1
90	Thyroid Dysfunction in Torsades de Pointes. JAMA Internal Medicine, 2017, 177, 1693.	2.6	1

#	Article	IF	CITATIONS
91	Visual Vignette. Endocrine Practice, 2012, 18, 426-426.	1.1	1
92	Glycemic Variability, Glycated Hemoglobin, and Cardiovascular Complications: Still a Dilemma in Clinical Practice. Advances in Therapy, 2021, , 1.	1.3	1
93	Current and emerging drugs for the treatment of atherosclerosis: the evidence to date. Expert Review of Cardiovascular Therapy, 0, , 1-13.	0.6	1
94	Care of patients with diabetes who are undergoing surgery. JAAPA: Official Journal of the American Academy of Physician Assistants, 2007, 20, 36.	0.1	0
95	PARASELLAR MENINGIOMA RESEMBLING A PITUITARY TUMOR. Endocrine Practice, 2007, 13, 86-88.	1.1	0
96	Visual Vignette. Endocrine Practice, 2018, 24, 1110.	1.1	0
97	The Role of Inflammation in Diabetes and Its Complications. Southern Medical Journal, 2006, 99, 8-9.	0.3	Ο